Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
Why now
Thesis: Clinical update on established drug, low market impact
Catalyst to watch: Positive or negative trial readouts
Main risk: Data could disappoint versus expectations
Why it matters
Conference data on an existing drug rarely changes revenue outlook without new efficacy or label news.
Details
STOCKHOLM, Sept. 24, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026), taking place 26-29 September...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 08:53 UTC